Literature DB >> 31685533

Flexible Cobamide Metabolism in Clostridioides (Clostridium) difficile 630 Δerm.

Amanda N Shelton1, Xun Lyu2, Michiko E Taga3.   

Abstract

Clostridioides (Clostridium) difficile is an opportunistic pathogen known for its ability to colonize the human gut under conditions of dysbiosis. Several aspects of its carbon and amino acid metabolism have been investigated, but its cobamide (vitamin B12 and related cofactors) metabolism remains largely unexplored. C. difficile has seven predicted cobamide-dependent pathways encoded in its genome in addition to a nearly complete cobamide biosynthesis pathway and a cobamide uptake system. To address the importance of cobamides to C. difficile, we studied C. difficile 630 Δerm and mutant derivatives under cobamide-dependent conditions in vitro Our results show that C. difficile can use a surprisingly diverse array of cobamides for methionine and deoxyribonucleotide synthesis and can use alternative metabolites or enzymes, respectively, to bypass these cobamide-dependent processes. C. difficile 630 Δerm produces the cobamide pseudocobalamin when provided the early precursor 5-aminolevulinic acid or the late intermediate cobinamide (Cbi) and produces other cobamides if provided an alternative lower ligand. The ability of C. difficile 630 Δerm to take up cobamides and Cbi at micromolar or lower concentrations requires the transporter BtuFCD. Genomic analysis revealed genetic variations in the btuFCD loci of different C. difficile strains, which may result in differences in the ability to take up cobamides and Cbi. These results together demonstrate that, like other aspects of its physiology, cobamide metabolism in C. difficile is versatile.IMPORTANCE The ability of the opportunistic pathogen Clostridioides difficile to cause disease is closely linked to its propensity to adapt to conditions created by dysbiosis of the human gut microbiota. The cobamide (vitamin B12) metabolism of C. difficile has been underexplored, although it has seven metabolic pathways that are predicted to require cobamide-dependent enzymes. Here, we show that C. difficile cobamide metabolism is versatile, as it can use a surprisingly wide variety of cobamides and has alternative functions that can bypass some of its cobamide requirements. Furthermore, C. difficile does not synthesize cobamides de novo but produces them when given cobamide precursors. A better understanding of C. difficile cobamide metabolism may lead to new strategies to treat and prevent C. difficile-associated disease.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  5-aminolevulinic acid; Clostridioides difficilezzm321990; Clostridium difficilezzm321990; cobalamin; cobamide; corrinoid enzymes; methionine synthase; nutrient transport; ribonucleotide reductase; vitamin B12zzm321990

Mesh:

Substances:

Year:  2020        PMID: 31685533      PMCID: PMC6941526          DOI: 10.1128/JB.00584-19

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  93 in total

1.  Conjugative plasmid transfer from Escherichia coli to Clostridium acetobutylicum.

Authors:  D R Williams; D I Young; M Young
Journal:  J Gen Microbiol       Date:  1990-05

2.  The structure of Escherichia coli BtuF and binding to its cognate ATP binding cassette transporter.

Authors:  Elizabeth L Borths; Kaspar P Locher; Allen T Lee; Douglas C Rees
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-10       Impact factor: 11.205

Review 3.  Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Gut Microbes       Date:  2013-12-11

4.  Cobamide structure depends on both lower ligand availability and CobT substrate specificity.

Authors:  Terence S Crofts; Erica C Seth; Amrita B Hazra; Michiko E Taga
Journal:  Chem Biol       Date:  2013-09-19

Review 5.  The emerging metabolic view of Clostridium difficile pathogenesis.

Authors:  Andrew J Hryckowian; Kali M Pruss; Justin L Sonnenburg
Journal:  Curr Opin Microbiol       Date:  2016-12-19       Impact factor: 7.934

6.  Clostridium difficile transcriptome analysis using pig ligated loop model reveals modulation of pathways not modulated in vitro.

Authors:  Joy Scaria; Tavan Janvilisri; Susan Fubini; Robin D Gleed; Sean P McDonough; Yung-Fu Chang
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

7.  Regiospecific formation of cobamide isomers is directed by CobT.

Authors:  Terence S Crofts; Amrita B Hazra; Jennifer L A Tran; Olga M Sokolovskaya; Vadim Osadchiy; Omer Ad; Jeffrey Pelton; Stefan Bauer; Michiko E Taga
Journal:  Biochemistry       Date:  2014-12-05       Impact factor: 3.162

8.  Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids.

Authors:  Jason D Kang; Christopher J Myers; Spencer C Harris; Genta Kakiyama; In-Kyoung Lee; Bong-Sik Yun; Keiichi Matsuzaki; Megumi Furukawa; Hae-Ki Min; Jasmohan S Bajaj; Huiping Zhou; Phillip B Hylemon
Journal:  Cell Chem Biol       Date:  2018-10-25       Impact factor: 8.116

9.  Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees.

Authors:  Ivica Letunic; Peer Bork
Journal:  Nucleic Acids Res       Date:  2016-04-19       Impact factor: 16.971

10.  Clostridium difficile Modulates the Gut Microbiota by Inducing the Production of Indole, an Interkingdom Signaling and Antimicrobial Molecule.

Authors:  Charles Darkoh; Kimberly Plants-Paris; Dayna Bishoff; Herbert L DuPont
Journal:  mSystems       Date:  2019-03-19       Impact factor: 6.496

View more
  2 in total

1.  Direct Cobamide Remodeling via Additional Function of Cobamide Biosynthesis Protein CobS from Vibrio cholerae.

Authors:  Amy T Ma; Joris Beld
Journal:  J Bacteriol       Date:  2021-07-08       Impact factor: 3.490

2.  Identification of a Novel Cobamide Remodeling Enzyme in the Beneficial Human Gut Bacterium Akkermansia muciniphila.

Authors:  Kenny C Mok; Olga M Sokolovskaya; Alexa M Nicolas; Zachary F Hallberg; Adam Deutschbauer; Hans K Carlson; Michiko E Taga
Journal:  mBio       Date:  2020-12-08       Impact factor: 7.867

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.